In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for ...
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS Newswir ...